Pulmatrix stockholders approve merger proposals; CSRC clearance still outstanding

Pulmatrix, Inc.

All seven proposals approved by stockholders at June 16 special meeting, including issuance of shares for Cullgen merger.
Reverse stock split authorized at ratio of 1-for-2 to 1-for-10, with final ratio to be set by board; authorized shares increased to 250M.
Merger remains subject to CSRC approval under China's Trial Measures; Pulmatrix notes CSRC approval not yet received.
Richard Batycky re-elected as Class II director; CBIZ CPAs ratified as auditor for FY2025 (subject to change post-merger).
Proposal 1 (share issuance >20% and change of control) passed with 798,652 votes for, 65,788 against, 2,428 abstain.

item 5.07item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.